Anest. intenziv. Med. 2024;35(5):288-291 | DOI: 10.36290/aim.2024.049

Year 2024 in review - SepsisReview Article

Karvunidis T.1, 2, Královcová M.1
1 Jednotka intenzivní péče, I. interní klinika Fakultní nemocnice Plzeň a Lékařská fakulta v Plzni, Univerzita Karlova
2 Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova

This year's summary comments an antimicrobial treatment of serious infections based on selected publications. In the context of recent studies and meta-analyses, it discusses the method of administration of β-lactam antibiotics, new issues on their safety, and also considers the appropriate duration of such therapy.

Keywords: sepsis, septic shock, antimicrobial treatment.

Received: November 28, 2024; Revised: November 28, 2024; Accepted: November 28, 2024; Published: December 19, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karvunidis T, Královcová M. Year 2024 in review - Sepsis. Anest. intenziv. Med. 2024;35(5):288-291. doi: 10.36290/aim.2024.049.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 19.12.2025

    References

    1. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020 Jan 18;395(10219):200-211. doi: 10.1016/S0140-6736(19)32989-7. PMID: 31954465; PMCID: PMC6970225. Go to original source... Go to PubMed...
    2. Fleischmann­‑Struzek C, Mellhammar L, Rose N, Cassini A, Rudd KE, Schlattmann P, et al. Incidence and mortality of hospital- and ICU­‑treated sepsis: results from an updated and expanded systematic review and meta­‑analysis. Intensive Care Med. 2020 Aug;46(8):1552-1562. doi: 10.1007/s00134-020-06151-x. Epub 2020 Jun 22. PMID: 32572531; PMCID: PMC7381468. Go to original source... Go to PubMed...
    3. De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, et al. Risk factors for target non­‑attainment during empirical treatment with β­‑lactam antibiotics in critically ill patients. Intensive Care Med. 2014 Sep;40(9):1340-51. doi: 10.1007/s00134-014-3403-8. Epub 2014 Jul 23. Erratum in: Intensive Care Med. 2015 May;41(5):969. doi: 10.1007/s00134-015-3772-7. Dosage error in article text. PMID: 25053248. Go to original source... Go to PubMed...
    4. Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T, et al. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther. 2005 Aug;43(8):360-9. doi: 10.5414/cpp43360. PMID: 16119511. Go to original source... Go to PubMed...
    5. Roberts JA, Abdul­‑Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus Intermittent β­‑Lactam Infusion in Severe Sepsis. A Meta­‑analysis of Individual Patient Data from Randomized Trials. Am J Respir Crit Care Med. 2016 Sep 15;194(6):681-91. doi: 10.1164/rccm.201601-0024OC. PMID: 26974879. Go to original source... Go to PubMed...
    6. Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME. Prolonged versus short­‑term intravenous infusion of antipseudomonal β­‑lactams for patients with sepsis: a systematic review and meta­‑analysis of randomised trials. Lancet Infect, DiS. 2018 Jan;18(1):108-120. doi: 10.1016/S1473-3099(17)30615-1. Epub 2017 Nov 5. PMID: 29102324. Go to original source... Go to PubMed...
    7. Monti G, Bradic N, Marzaroli M, Konkayev A, Fominskiy E, Kotani Y, et al; MERCY Investigators. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial. JAMA. 2023 Jul 11;330(2):141-151. doi: 10.1001/jama.2023.10598. PMID: 37326473; PMCID: PMC10276329. Go to original source... Go to PubMed...
    8. Santacruz CA, Pereira AJ, Celis E, Vincent JL. Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review. Crit Care Med. 2019 Dec;47(12):1680-1691. doi: 10.1097/CCM.0000000000004000. PMID: 31567349. Go to original source... Go to PubMed...
    9. Teo J, Liew Y, Lee W, Kwa AL­‑H. Prolonged infusion versus intermittent boluses of β­‑lactam antibiotics for treatment of acute infections: a meta­‑analysis. Int J Antimicrob Agents. 2014;43(5):403-411. doi:10.1016/j.ijantimicag.2014. 01. 027. Go to original source...
    10. Dulhunty JM, Brett SJ, De Waele JJ, Rajbhandari D, Billot L, Cotta MO, et al; BLING III Study Investigators. Continuous vs Intermittent β­‑Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. JAMA. 2024 Aug 27;332(8):629-637. doi: 10.1001/jama.2024.9779. PMID: 38864155; PMCID: PMC11170452. Go to original source... Go to PubMed...
    11. Abdul­‑Aziz MH, Hammond NE, Brett SJ, Cotta MO, De Waele JJ, Devaux A, et al. Prolonged vs Intermittent Infusions of β­‑Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta­‑Analysis. JAMA. 2024 Aug 27;332(8):638-648. doi: 10.1001/jama.2024.9803. PMID: 38864162; PMCID: PMC11170459. Go to original source... Go to PubMed...
    12. Li X, Long Y, Wu G, Li R, Zhou M, He A, et al. Prolonged vs intermittent intravenous infusion of β­‑lactam antibiotics for patients with sepsis: a systematic review of randomized clinical trials with meta­‑analysis and trial sequential analysis. Ann Intensive Care. 2023 Dec 5;13(1):121. doi: 10.1186/s13613-023-01222-w. PMID: 38051467; PMCID: PMC10697919. Go to original source... Go to PubMed...
    13. Lokhandwala A, Patel P, Isaak AK, Faizan Yousaf R, Maslamani ANJ, Khalil SK, et al. Comparison of the Effectiveness of Prolonged Infusion and Intermittent Infusion of Meropenem in Patients With Sepsis: A Meta­‑Analysis. Cureus. 2023 Oct 13;15(10):e46990. doi: 10.7759/cureus.46990. PMID: 38022273; PMCID: PMC10640903. Go to original source... Go to PubMed...
    14. Zhao Y, Zang B, Wang Q. Prolonged versus intermittent β­‑lactam infusion in sepsis: a systematic review and meta­‑analysis of randomized controlled trials. Ann Intensive Care. 2024;14(1):30. doi:10.1186/s13613-024-01263-9. Go to original source... Go to PubMed...
    15. Bellos I, Karageorgiou V, Pergialiotis V, Perrea DN. Acute kidney injury following the concurrent administration of antipseudomonal β­‑lactams and vancomycin: a network meta­‑analysis. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect, DiS. 2020;26(6):696-705. doi:10.1016/j.cmi.2020. 03. 019. Go to original source...
    16. Blevins AM, Lashinsky JN, McCammon C, Kollef M, Micek S, Juang P. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin­‑Tazobactam, Cefepime, or Meropenem. Antimicrob Agents Chemother. 2019;63(5). doi:10.1128/AAC.02658-18. Go to original source... Go to PubMed...
    17. O'Callaghan K, Hay K, Lavana J, McNamara JF. Acute kidney injury with combination vancomycin and piperacillin­‑tazobactam therapy in the ICU: A retrospective cohort study. Int J Antimicrob Agents. 2020;56(1):106010. doi:10.1016/j.ijantimicag.2020.106010. Go to original source... Go to PubMed...
    18. Qian ET, Casey JD, Wright A, Wang L, Shotwell MS, Siemann JK, et al; Vanderbilt Center for Learning Healthcare and the Pragmatic Critical Care Research Group. Cefepime vs Piperacillin­‑Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial. JAMA. 2023 Oct 24;330(16):1557-1567. doi: 10.1001/jama.2023.20583. PMID: 37837651; PMCID: PMC10576861. Go to original source... Go to PubMed...
    19. Chanderraj R, Admon AJ, He Y, Nuppnau M, Albin OR, Prescott HC, et al. Mortality of Patients With Sepsis Administered Piperacillin­‑Tazobactam vs Cefepime. JAMA Intern Med. 2024 Jul 1;184(7):769-777. doi: 10.1001/jamainternmed.2024.0581. PMID: 38739397; PMCID: PMC11091820. Go to original source... Go to PubMed...
    20. Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Anti­‑pseudomonal beta­‑lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta­‑lactams. Cochrane database Syst Rev. 2010;2010(11):CD005197. doi:10.1002/14651858.CD005197.pub3. Go to original source... Go to PubMed...
    21. Teshome BF, Vouri SM, Hampton N, Kollef MH, Micek ST. Duration of Exposure to Antipseudomonal β­‑Lactam Antibiotics in the Critically Ill and Development of New Resistance. Pharmacotherapy. 2019;39(3):261-270. doi:10.1002/phar.2201. Go to original source... Go to PubMed...
    22. Arulkumaran N, Routledge M, Schlebusch S, Lipman J, Conway Morris A. Antimicrobial­‑associated harm in critical care: a narrative review. Intensive Care Med. 2020;46(2):225-235. doi:10.1007/s00134-020-05929-3. Go to original source... Go to PubMed...
    23. Miller M, Singer M. Do antibiotics cause mitochondrial and immune cell dysfunction? A literature review. J Antimicrob Chemother. 2022;77(5):1218-1227. doi:10.1093/jac/dkac025. Go to original source... Go to PubMed...
    24. Sudo RYU, Câmara MCC, Kieling SV, Marques IR, Mesquita Y, Piepenbrink BE, et al. Shorter versus longer duration of antibiotic treatment in children with bacterial meningitis: a systematic review and meta­‑analysis. Eur J Pediatr. 2024 Jan;183(1):61-71. doi: 10.1007/s00431-023-05275-8. Epub 2023 Oct 23. PMID: 37870611. Go to original source... Go to PubMed...
    25. Mo Y, Booraphun S, Li AY, Domthong P, Kayastha G, Lau YH, et al; REGARD­‑VAP investigators. Individualised, short­‑course antibiotic treatment versus usual long­‑course treatment for ventilator­‑associated pneumonia (REGARD­‑VAP): a multicentre, individually randomised, open­‑label, non­‑inferiority trial. Lancet Respir Med. 2024 May;12(5):399-408. doi: 10.1016/S2213-2600(23)00418-6. Epub 2024 Jan 22. PMID: 38272050. Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.